Effect of Coffee Consumption on the Glycemic Index of Khalas Dates Tested in Healthy and Diabetic Subjects

NCT ID: NCT01422668

Last Updated: 2011-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate the composition of Khalas, a very common type of dates used in the UAE and to determine the effects of drinking Arabic coffee on the results of GI tests in both healthy and diabetic subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:The consumption of dates along with coffee is a deeply rooted habit in many societies. This study was designed to determine the effect of coffee consumption on the glycemic index of a common variety of dates (Khalas) tested in healthy subjects and individuals with type 2 diabetes mellitus.

Methods:Composition analysis was carried out for Khalas dates (Tamer stage) and the weight of the dates flesh equivalent to 50 g of available carbohydrate was calculated. The study subjects were thirteen healthy volunteers with a mean (± SD) age of 40.2 ± 6.7 years and ten participants with type 2 diabetes mellitus (controlled on lifestyle measures and/or metformin) with a mean HbA1c (± SD) of 6.6 ± (0.7 %) and a mean age (± SD) of 40.8 ± 5.7 years. Each subject was tested on five separate days with 50 g of glucose (on 3 occasions) and 50 g equivalent of available carbohydrates from the dates without coffee (on one occasion) and with coffee (on another occasion). Capillary glucose was measured in the healthy subjects at 0, 15, 30, 45, 60, 90 and 120 min and for the diabetics at 0, 30, 60, 90, 120, 150 and 180 min. The glycemic indices were determined as ratios of the incremental areas under the response curves for the dates alone/with coffee compared to glucose. Statistical analyses were performed using Student's t-tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GI of Khalas dates

The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.

Group Type ACTIVE_COMPARATOR

Khalas dates

Intervention Type OTHER

every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates

GI of the Khalas dates with Coffee

measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.

Group Type EXPERIMENTAL

Khalas dates

Intervention Type OTHER

every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Khalas dates

every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* required that those in the healthy group were healthy and in the diabetes group that their diabetes was controlled (HbA1c ≤8%) on diet with or without metformin

Exclusion Criteria

* morbid obesity (BMI \> 40 kg/m2)
* pre diabetes
* pregnancy
* presence of gastroenterological disorders
* alimentary tract surgery
* a history of gastroenteritis in the prior six months
* any alcohol intake
* smoking
* taking any medications (except metformin)
* poorly controlled diabetes (HbA1c \> 8%) and the presence of acute or chronic diseases
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United Arab Emirates University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juma Alkaabi

Assistant Professor of Medicine, Faculty of Medicine and Health Sciences

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juma M Alkaabi, MD

Role: PRINCIPAL_INVESTIGATOR

Assistant professor Internal Medicine Department FMHS UAE University

Bayan Al-Dabbag, PhD

Role: STUDY_CHAIR

FMHS UAE university

Hussein Saadi, MD

Role: STUDY_CHAIR

Professor of Medicine, FMHS UAE University

Salah Gariballa, MD

Role: STUDY_CHAIR

Professor of Medicine FMHS UAE University

Yasin Javed, Msc

Role: STUDY_CHAIR

FMHS UAE University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine and Health Sciences UAE University

Al Ain City, AB, United Arab Emirates

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Arab Emirates

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UAEU: GI Dates Study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.